Altus Wealth Group’s Haemonetics HAE Stock Holding History

Altus Wealth Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-41	Closed	-$5K	–	418
2020 Q4	$5K	Buy	+41	New	+$4.41K	﹤0.01%	650

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altus Wealth Group's HAE Position: Q1 2021 in Review

Altus Wealth Group sold out of Haemonetics (HAE) in Q1 2021, closing a stake of 41 shares — an estimated $5K sold.

Altus Wealth Group first reported a position in HAE in Q4 2020 and held it in 1 quarter. The position peaked at $5K in Q4 2020. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.

Altus Wealth Group reported no remaining Haemonetics position as of Q1 2021 after selling out during the quarter.
Altus Wealth Group sold 41 Haemonetics shares in Q1 2021, an estimated $5K.
Altus Wealth Group first reported a position in Haemonetics in Q4 2020 and held it in 1 quarter.
Altus Wealth Group's Haemonetics position peaked at $5K in Q4 2020.
296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.

Based on Altus Wealth Group's 13F filing for Q1 2021, filed 14 May 2021.